|
[posting]61619211[/posting]19. Taxation The Company reconciles the expected income tax expense at the average US statutory income tax rate of 21% to the amount recognized in the statement ofoperations. The Company’s income tax expense is calculated based on gross profits not including 280E deductions. The Company’s US income is apportioned to the State of Oregon, Nevada and California, as there are no revenues in other states. The production and sale of marijuana and related products for medical purposes is legal in the State of Oregon and therefore normal business expenses are deductible at the state level. The tax rate in the State of Oregon is the greater of 6.6% or the corporate gross receipts minimum tax. Internal Revenue Code (“IRC”) Section 280E denies, at the US federal level, deductions and credits attributable to a trade or business trafficking in controlled substances. Case law shows that “cost of goods sold” has been permitted as a deduction in determining taxable income. Because the Company is subject to IRC Section 280E, the Company has computed its US tax based on gross receipts less cost of goods sold. The tax provision for the six months ended June 30, 2019, has been prepared based on the assumption “cost of goods sold” is a valid expense for income tax purposes. Quelle: https://www.sedar.com/GetFile.do?lang=EN&docClass=5&issuerNo… Ok, dann sind diese zusätzlichen Ausgaben scheinbar nicht dem Kerngeschäft zurechenbar und daher nicht abziehbar vom Bruttogewinn. Jetzt muss ich mal weiter recherchieren wie das sein kann? \ud83e\udd14 |
|
| aus der Diskussion: | Halo Collective ( A9KN) ehemals Halo Labs |
| Autor (Datum des Eintrages): | HG_30042018 (03.10.19 15:59:39) |
| Beitrag: | 5,111 von 49,647 (ID:61619289) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |